phase 3

Abivax’s crash may be the market overpricing a safety scare after a real Phase 3 win

Abivax just posted the kind of Phase 3 efficacy biotech investors wait years to see, and the stock still got cut nearly in half because the market fixated on a safety overhang. That risk is real, but a 44.1% one-day collapse looks more like panic repricing than a fair read on a drug that delivered 50%+ remission in maintenance.